SEEGENE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22,400 KRW | +2.52% |
|
+0.22% | -2.18% |
| Mar. 14 | Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 24 | Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 67.88 and 24.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.18% | 762M | C+ | ||
| -4.81% | 3.15B | C | ||
| +31.37% | 2.99B | D+ | ||
| -14.73% | 2.15B | - | B- | |
| -14.39% | 1.8B | C+ | ||
| +70.99% | 1.49B | B- | ||
| +23.17% | 770M | C- | ||
| -20.41% | 575M | C- | ||
| +3.18% | 308M | - | - | |
| +6.63% | 210M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A096530 Stock
- Ratings Seegene, Inc.